NEW YORK, NY--(Marketwire -03\/19\/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. The iShares NASDAQ Biotechnology Index (IBB) is currently up more than 16 percent year to date, reflecting an uptick in investor sentiment. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cardium Therapeutics Inc. (AMEX: CXM - News) & BioSante Pharmaceuticals Inc. (NASDAQ: BPAX - News). Access to the full company reports can be found at: <\/p>\n
http:\/\/www.paragonreport.com\/CXM<\/a> <\/p>\n http:\/\/www.paragonreport.com\/BPAX<\/a> <\/p>\n Earlier this month the Biotechnology Industry Organization applauded the Faster Access to Specialized Treatments (FAST) Act. According to BIO the legislation will modernize the Accelerated Approval pathway to expedite the development of modern, targeted, and personalized therapies for patients suffering from serious and life-threatening diseases. <\/p>\n BIO President and CEO Jim Greenwood says the FAST act will speed access to innovative new therapies and cures to patients living with debilitating and life-threatening diseases such as Parkinson's, Alzheimer's, diabetes and numerous rare diseases for which there is currently no treatment or cure. <\/p>\n The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http:\/\/www.paragonreport.com<\/a> and get exclusive access to our numerous stock reports and industry newsletters. <\/p>\n Cardium Therapeutics is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Earlier this month the company reported that it is making its MedPodium Nutra-Apps products available across the United States by working with Nutritional Products International (NPI) and InHealth Media. <\/p>\n BioSante is developing a portfolio of cancer vaccines, with 17 Phase I and Phase II clinical trials currently on-going. Four of these vaccines have been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA). Earlier this month the company reported that its net loss was $51.6 million or $0.52 per share for the year ended December 31, 2011, compared to a net loss of $46.2 million or $0.70 per share for 2010. <\/p>\n The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http:\/\/www.paragonreport.com\/disclaimer<\/a> <\/p>\n<\/p>\n Visit link: NEW YORK, NY--(Marketwire -03\/19\/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. The iShares NASDAQ Biotechnology Index (IBB) is currently up more than 16 percent year to date, reflecting an uptick in investor sentiment. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cardium Therapeutics Inc. Continue reading
\nFAST Act to Modernize Approval Process -- Cardium and BioSante Poised to Benefit<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"